OnabotulinumtoxinA in Oral-Refractory Pediatric Neurogenic Detrusor Overactivity
A ten-year-old boy with spina bifida who has failed his one tolerable oral agent, and has a wheelchair basketball tournament in ten weeks, forces the real question in this pivot into the open: not whether botulinum toxin works, but where it sits relative to augmentation cystoplasty.
Julian F. plays point guard for his regional wheelchair basketball league and has a tournament in ten weeks that he has been talking about since the season schedule came out — a fact that has entered every conversation about timing, whether or not anyone in the room raised it first. He is ten years old, has a thoracolumbar myelomeningocele, and has been on maximum-tolerated oxybutynin (10mg extended-release daily) for two years, but over the past six months has developed breakthrough incontinence between catheterizations severe enough that he now changes clothes at school at least once most weeks.
Repeat urodynamics this month showed a maximum cystometric capacity of 150mL, well below his age-predicted capacity of roughly 330mL, with detrusor pressures reaching 45cm H2O well before that volume — findings essentially unchanged from oxybutynin's own ceiling effect rather than reflecting a new deterioration. He has tried and not tolerated a trial of solifenacin (dry mouth severe enough that he stopped taking it after ten days), which leaves him genuinely oral-therapy-refractory rather than simply undertreated. OnabotulinumtoxinA received FDA approval for pediatric neurogenic detrusor overactivity in patients five years and older, specifically for those intolerant of or inadequately responsive to anticholinergics, based on Austin and colleagues' randomized phase 3 trial in more than one hundred children that found real gains in bladder capacity and continence episodes. The alternative most often raised at this point in a child's course isn't another drug at all — it's augmentation cystoplasty, a bowel-segment bladder enlargement that is more durable than botulinum's roughly six-to-nine-month effect but is a major abdominal surgery with its own long-term complications, including a real risk of bladder stones and, rarely, malignancy in the augmented segment decades later.
A temporary fix or the bigger conversation
He's failed the one oral agent he could tolerate, and botulinum toxin's effect runs six to nine months at best — meaning we'd be committing him to repeat injections under anesthesia, likely two or three times a year, indefinitely. Augmentation cystoplasty is more surgery up front, but it's a durable answer to a problem that isn't going away, and starting that conversation now, while he's otherwise healthy and before repeat anesthesia exposures accumulate, is better than deferring it by a year of temporary fixes.
You're right that augmentation is the more durable fix, and I'm not arguing against ever having that conversation. But “better to have it now” assumes now is a neutral time to ask a ten-year-old and his family to weigh a major bowel-segment surgery with lifelong stone and malignancy-surveillance implications, and it isn't — he has a tournament in ten weeks he's been anticipating all season, and asking a family to make a permanent decision under that kind of time pressure risks a worse decision, not a faster good one.
Botulinum toxin isn't just a stopgap here; it's an outpatient procedure with days, not months, of recovery, which means it can actually answer part of the augmentation question — how much of his incontinence is detrusor overactivity versus something structural — without foreclosing anything.
Both of those are real considerations, and they don't have to compete: give the botox injection now, scheduled well clear of the tournament, and treat it explicitly as diagnostic as well as therapeutic. If his capacity and continence improve substantially, that's real evidence his problem is still primarily detrusor-driven and augmentation can be deferred, possibly for years. If it doesn't move his numbers much, that itself is useful information for the augmentation conversation the surgeon wants to have — just conducted from better evidence than we have today, not instead of it.
Julian received his onabotulinumtoxinA injection five weeks before the tournament, with follow-up urodynamics planned at ten weeks to measure the actual capacity and pressure change rather than go by symptom report alone.
Not agreed: how good a result would need to be to defer the augmentation conversation for good, versus just for now. The rehabilitation physician would treat a strong response as reason to keep repeating botox indefinitely if it keeps working; the surgeon views repeat anesthesia exposure over years as its own cost that a single durable surgery avoids, regardless of how well any given round of botox performs.